News

Read the latest news about issues affecting the neuromuscular disease community.

MDA logo
Blog Post

Catalyst Pharmaceuticals Announces Positive Results from Phase 2b Trial of Firdapse in Patients with Muscle-Specific Kinase Antibody Positive Myasthenia Gravis (MuSK-MG)

By Jeanene Swanson | January 30, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Brainstorm Cell Therapeutics Seeks Participants for a Phase 3 ALS Study

By MDA Staff | January 16, 2019
MDA logo
Blog Post

FDA Awards Fast Track Status to RNS60, Revalesio’s Investigational Therapy for ALS

By Jeanene Swanson | January 16, 2019
Blog Post

MDA Awards Venture Philanthropy Grant to AcuraStem to Develop Treatment for ALS

By Jeanene Swanson | January 15, 2019
Blog Post

Newborn Screening for DMD and BMD: MDA Needs Your Help

By MDA Staff | January 15, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Orphazyme Seeks Participants for a Phase 3 ALS Study

By MDA Staff | January 11, 2019
clinical-trial-alert-image
Blog Post

Clinical Trial Alert: Catabasis Seeks Participants for a Phase 3 DMD Study

By MDA Staff | January 10, 2019
Blog Post

Wave Life Sciences Announces Phase 2/3 Duchenne Muscular Dystrophy Clinical Trial of Suvodirsen (WVE-210201) Selected for FDA Complex Innovative Trial Designs Pilot Program

By Jeanene Swanson | January 8, 2019
Blog Post

FDA Grants Orphan Drug Designation to Myonexus Therapeutics’ MYO-102 Gene Therapy Drug for Limb-Girdle Muscular Dystrophy Type 2D

By Jeanene Swanson | January 4, 2019
FDA APPROVED text on sticker on blue background with pen
Blog Post

FDA Announces the Approval of TIGLUTIK, an Oral Suspension Form of riluzole, for the Treatment of ALS

By MDA Staff | September 10, 2018